Kalaris Therapeutics Stock (NASDAQ:KLRS)
Previous Close
$3.63
52W Range
$3.03 - $11.88
50D Avg
$4.09
200D Avg
$6.41
Market Cap
$75.74M
Avg Vol (3M)
$255.31K
Beta
0.21
Div Yield
-
KLRS Company Profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.